NewVac signs license and co-development agreement with Janssen to advance novel drug for treatment of solid tumors
San Francisco, CA, January 07, 2013 - NewVac LLC (a ChemRar company, resident of the Skolkovo Innovation Center in Russia) announced today that it has entered into a co-license agreement with Janssen Pharmaceutica, NV (Janssen). Under the terms of the agreement Janssen grants NewVac the exclusive rights for the development and commercialization of Janssen’s quisinostat an innovative next generation Histone Deacetylase Inhibitor (HDACi) program - in Russia and several other Eastern European countries. Quisinostat will be investigated for the treatment of patients with solid tumors in combination with standard of care agents.
Under the arrangement, NewVac will develop quisinostat including R&D support to clinical trials. Janssen will provide its expertise in external global clinical trials.
The agreement with Janssen is an important component of NewVac’s strategy, which is designed to create value for the Russian people through progressive partnerships aimed at the modernization of the pharmaceutical industry, accelerating the development of medical innovations, and to contribute to the extension of life expectancy and improvement of quality-of-life for Russian patients.
Nikolay Savchuk, Chairman of the Board of NewVac, noted: "Our goal is to create an innovative world-class biomedical platform for the treatment of oncologic diseases based on molecularly targeted compounds including but not limited to immunological cancer therapies in Russia. We were looking very hard for a next generation HDAC compound which has potential to demonstrate clinical activity in solid tumors and especially with potential for clinically meaningful improvement of outcomes in resistant or refractory disease. NewVac will initiate solid tumor combination therapy studies which are accompanied by translational efforts. We are honored to commit our research organization to such a noble cause and we plan to start and conduct those clinical studies in Russia in 2013. NewVac will continue to help making innovative and highly efficacious cancer therapies more easily accessible to Russian patients."
About NewVac LLC
NewVac LLC is a subsidiary of ChemRar High Tech Center, the top Russian non-governmental research and development center for life sciences. NewVac's major objective is development, manufacturing and advancement of combination medicines and personalized research to treat cancer. NewVac became one of the first residents of Skolkovo innovation cluster in Russia in 2010 and continues to develop and manufacture personalized oncovaccines, small molecule adjuvants and diagnostics.
Contacts for media:
Phone: + 7(926)-206-78-71
SAN DIGEO, CA, January 3, 2017 – NewVac LLC reported meeting all primary endpoints in the Phase II Clinical Trial of quisinostat, novel selective...
San Francisco, CA, January 07, 2013 - NewVac LLC (a ChemRar company, resident of the Skolkovo Innovation Center in Russia) announced today that it...
Oleg Kouzbit, Online News Managing Editor — In a new international technology transfer success story, Russian biotech company NewVac announces...